CAD advances boost mammography workflow
R2 Technology is making machines smarter and, in the process, easing the transition to digital mammography.
R2 Technology is making machines smarter and, in the process, easing the transition to digital mammography.
The CAD developer's Citra Mammography Applications Suite, launched at the 2005 RSNA meeting, includes software tools that automatically scale mammograms to the display window, sizing the previous mammogram with the current image, regardless of the system used to capture the images or the amount of compression placed on the breasts.
In a separate development, the company enhanced its ImageChecker mammography CAD technology. One new feature, built into Version 8.1, identifies regions of breast tissue that contain both a mass and calcifications. Another assigns variable-sized CAD marks to indicate the potential for malignancy.
This latest version also allows users to set the sensitivity of the machine to flag more or fewer anomalies. Separate controls are available for microcalcifications and for masses.
The introductions reflect a corporate strategy to promote the use of CAD as a way to make radiologists' lives easier. This strategy, and how it will affect R2 products in the future, will be featured in the next issue of DI SCAN, available online Dec. 19.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
